LARA
Trial Description:
A Multicentre Phase II trial of Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas
Lead Cooperative Group:
Participating Groups:
Trial Number:
Disease Site:
Ovarian & Endometrial
Trial Status:
Recruiting
Contact person:
dtan